Rani Therapeutics Holdings, Inc. (RANI)
Automate Your Wheel Strategy on RANI
With Tiblio's Option Bot, you can configure your own wheel strategy including RANI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RANI
- Rev/Share 0.0307
- Book/Share -0.16
- PB -6.1267
- Debt/Equity -6.462
- CurrentRatio 0.8834
- ROIC -2.5243
- MktCap 32217908.0
- FreeCF/Share -1.033
- PFCF -0.9327
- PE -0.6283
- Debt/Assets 0.8186
- DivYield 0
- ROE -24.3705
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Rani Therapeutics Announces Research Agreement with Chugai
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Research agreement is evaluating feasibility of applying Rani's oral delivery technology to Chugai's antibodies against undisclosed targets - SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company has entered into a Research Agreement on 13th August, 2024, for two molecules with undisclosed targets provided by Chugai Pharmaceutical Co., Ltd.
Read More
About Rani Therapeutics Holdings, Inc. (RANI)
- IPO Date 2021-07-30
- Website https://www.ranitherapeutics.com
- Industry Biotechnology
- CEO Mr. Talat Imran
- Employees 105